在急性心肌梗塞中,与前负载的阿尔泰相比,单玻尿酸:ASSENT-2双盲随机试验
Lancet (London, England)
|September 4, 1999
概括
在急性心肌梗塞患者中,丁甲和高甲显示出相当于30天死亡率. 甲提供了更容易的管理,可能加快再注射疗法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 玻尿酸纤维解药疗法对于急性心肌梗塞 (AMI) 的早期再注血至关重要.
- 基因工程 alteplase 变体的 Tenecteplase 提供了改善的纤维素特异性和对抑制剂的耐药性.
- 评估对alteplase的tenecteplase疗效和安全性对于治疗优化至关重要.
研究的目的:
- 在患有急性心肌梗塞的患者中,比较tenecteplase与alteplase的疗效和安全性.
- 为了确定与30天所有原因的死亡率相关的甲和高甲的等价性.
- 为了评估这两种纤维溶解剂之间的出血并发症和中风率的差异.
主要方法:
- 这是一项双盲,随机对照试验,涉及1021家医院的16949名患者.
- 患者在AMI发作6小时内接受了快速输液阿尔泰或单剂玻尿酸.
- 所有患者都接受了标准的阿司匹林和肝素治疗,主要结局是30天全因死亡率.
主要成果:
- 坦氏甲和阿尔特氏甲的30天死亡率相等 (6.18%和6.15%).
- 内出血的发病率与此相似,但丁氏甲显著减少了非大脑出血并发症,减少了对输血的需求.
- 30天后死亡或非致命性中风的综合结果在两组之间是可比的.
结论:
- 甲在减少急性心肌梗塞30天死亡率方面相当于阿尔特.
- 简化给药可能会导致更快的治疗开始和改善患者的治疗结果.
- 与alteplase相比,tenecteplase具有良好的安全性,并减少了出血并发症.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...